Inactive Instrument

Press Releases Five Prime Therapeutics, Inc.

Equities

FPRX

US33830X1046

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS	22-08-05	AQ
Amgen : Successfully Completes Acquisition Of Five Prime Therapeutics	21-04-19	AQ
FIVE PRIME THERAPEUTICS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	21-04-16	AQ
Amgen : Successfully Completes Acquisition Of Five Prime Therapeutics	21-04-16	PR
FIVE PRIME THERAPEUTICS, INC. : Other Events (form 8-K)	21-04-15	AQ
Five Prime Therapeutics : Annual Report (SEC Filing - 10-K)	21-03-22	PU
FIVE PRIME THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	21-03-22	AQ
FIVE PRIME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Five Prime Therapeutics - FPRX	21-03-11	BU
Five Prime Therapeutics : Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call	21-03-09	BU
FIVE PRIME THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	21-03-04	AQ
Amgen : To Acquire Five Prime Therapeutics For $1.9 Billion in Cash	21-03-04	PR
Five Prime Therapeutics : Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call	21-03-02	BU
Five Prime Therapeutics : to Participate in the Cowen 41st Annual Health Care Conference	21-02-26	BU
Five Prime Therapeutics : Corporate Overview February 2020	21-02-25	PU
Five Prime Therapeutics : to Participate in the SVB Leerink 10th Annual Global Healthcare Conference	21-02-22	BU
Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day	21-02-05	BU
FIVE PRIME THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)	21-01-15	AQ
Five Prime Therapeutics : Bema P2 Data Presentation KOL Event	21-01-15	PU
FIVE PRIME THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	21-01-15	AQ
Five Prime Therapeutics : Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ Cancers	21-01-15	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Five Prime Therapeutics, Inc.

Equities

FPRX

US33830X1046

Press Releases

Filters